Drug Profile


Alternative Names: Minnelide

Latest Information Update: 03 Sep 2013

Price : $50

At a glance

  • Originator University of Minnesota
  • Developer Minneamrita Therapeutics
  • Class Antineoplastics; Diterpenes; Epoxy compounds; Phenanthrenes; Phosphoric acid esters
  • Mechanism of Action HSP70 heat shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Aug 2013 Phase-I clinical trials in Gastrointestinal cancer (late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top